ASCO25: J&J’s trispecific antibody shows 100% response in Phase I multiple myeloma study
First-in-human data for the trispecific antibody “suggest a paradigm shift” for the relapsed/refractory multiple myeloma space.
First-in-human data for the trispecific antibody “suggest a paradigm shift” for the relapsed/refractory multiple myeloma space.
What's Your Reaction?
